

Kendte, invaliderende og livsbegrænsende gastro-intestinale senfølger. **Vi kan reducere omfang betydeligt med en målrettet indsats?**

Danske Kraeftforskningsdage, Odense, 1. september 2023

Peter Christensen, professor, overlæge, dr.med.

Nationalt forskningscenter for senfølger efter kræft i bækkenorganerne

Mave Tarm Kirurgi, Aarhus Universitetshospital



AUH Surgery
Surgical Research

#DKD2023

#SamarbejdeOmKraeft

Aarhus University Hospital

*'Jeg kunne ikke gå
en tur med hunden
uden'*





Low Anterior Resection Syndrome Score

Development and Validation of a Symptom-Based Scoring System for Bowel Dysfunction After Low Anterior Resection for Rectal Cancer


Katrine J. Emmertsen, MD,*† and Søren Laurberg, MD*

Annals of Surgery • Volume 255, Number 5, May 2012



AUH Surgery
Surgical Research

LARS score




0-20 = No LARS

21-29 = Minor LARS


30-42 = Major LARS

Quality of life | LARS vs. EORTC QLQ C30 FUNCTIONAL SCALES






Senfølger rammer flere organer samtidig



Tværfaglig Klinik for Senfølger efter kræft




Evaluering af effekten af behandling

Alle cancere i
bækkenorganer

Fundet ved:

- screening (tarmkræft) ca. 50%
- ambulante kontrolbesøg i andre afd
- egen læge

Klinik for Senfølger



- Mave- og Tarmkirurgi
- Lever- Mave- og Tarmsygdomme
- Urinvejskirurgisk afd.
- Gynækologisk afd.
- Smerteklinik
- Sexologisk center



ORIGINAL ARTICLE

Systematic screening for late sequelae after colorectal cancer—a feasibility study

Therese Juul^{1,2,3} | Annette Boesen Bräuner^{2,4} | Asbjørn Mohr Drewes^{3,5,6} |
Katrine Jøssing Emmertsen^{3,7} | Klaus Krogh^{3,8} | Søren Laurberg^{2,3} |
Michael Bødker Lauritzen^{9,10} | Ole Thorlacius-Ussing^{6,9} | Peter Christensen^{1,2,3} |
Danish Cancer Society Centre for Research on Survivorship and Late Adverse Effects after
Cancer in the Pelvic Organs Study Group

¹Department of Surgery, Aarhus University Hospital, Aarhus, Denmark

²Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

³Danish Cancer Society Centre for Research on Survivorship and Late Adverse Effects After Cancer in the Pelvic Organs, Aalborg, Denmark

⁴Department of Surgery, Regional Hospital Viborg, Viborg, Denmark

⁵Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark

⁶Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

⁷Department of Surgery, Regional Hospital Randers, Randers, Denmark

⁸Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aalborg, Denmark

⁹Department of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark

¹⁰Department of Surgery, North Denmark Regional Hospital, Hjørring, Denmark


Correspondence
Therese Juul, Department of Surgery,
Aarhus University Hospital, Aarhus,
Denmark.
Email: therjuul@rm.dk

Funding information
The study was funded by the Danish
Cancer Society, grant R192-A11536.
Therese Juul was partly supported by
the Novo Nordisk Foundation grant
NNF19OC0022988. The funders had no
role in study design, data collection and
analysis, decision to publish or preparation
of the manuscript.


Abstract
Aim: The aim of this study was to test the feasibility of a new method for systematic screening for late sequelae (LS) following colorectal cancer treatment.
Method: Patients with colorectal cancer from five Danish hospitals were invited to complete a survey about LS at 3, 12, 24 and 36 months after surgery as part of their follow-up. The survey consisted primarily of validated tools, supplemented by a few ad hoc items, measuring bowel, urinary and sexual dysfunction, pain and quality of life and an additional question regarding request for contact. Patients completed surveys electronically or on paper.
Results: Of the 1721 invited patients, 1386 (80.5%) were included (1085 with colon cancer and 301 with rectal cancer) of whom 72.5% responded electronically. Patients responding electronically were 7.6 years younger than those responding on paper ($P < 0.001$). Since some patients answered more than once, the dataset consisted of 2361 surveys. Patients with colon cancer requested phone contact in 19.0% of the surveys, and 8.4% were referred to treatment for LS, primarily bowel dysfunction. Among patients with rectal cancer, 30.8% requested phone contact and 16.2% were referred for treatment of LS, mainly due to bowel and sexual dysfunction.
Conclusion: This is the first paper investigating a new method of systematic screening for LS following colorectal cancer using electronic patient-reported outcome measures. The

2904 patienter svarprocent 80%

COLON CANCER



RECTAL CANCER



■ No action ■ Phone contact only ■ Phone + referral ■ No action ■ Phone contact only ■ Phone + referral

FIRST AID CASE



Medicines & Plasters



Sygeplejersker i front



Jeg kan
hjælpe!



BATHROOM POSTURE

detsundeliv.dk

Udredning og behandling af diarré efter kræft



Medicinliste

Gluten allergi? Mælkesukker- intolerance?
Kronisk tarmbetændelse? m.fl.

Overvækst af bakterier i tyndtarmen?

Manglende optagelse af galdesalte

Peristaltikforstyrrelser


Og hvad fandt vi så?

95 % mindst 1 ny diagnose

47 % > 1 ny diagnose

2/3 signifikant forbedring

1/4 nogen forbedring



ORIGINAL ARTICLE

Long-term gastrointestinal prospective pilot study of evaluation and effects of

Helene M. Larsen^{1,2,3} | Mira Mekl Peter Christensen^{1,3} | Asbjørn Mohr Søren Laurberg^{1,3} | Klaus Krogh^{2,3}
Centre for Research on Survivorship : Organs Study Group

¹Department of Surgery, Aarhus University Hospital, Aarhus, Denmark

²Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark

³Danish Cancer Society Centre for Research on Survivorship and Late Adverse Effects after Cancer in the Pelvic Organs, Aarhus/Aalborg, Denmark

⁴Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

⁵Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark

⁶Department of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark

Correspondence
Helene Mathilde Larsen, Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.
Email: hemala@clin.au.dk

Funding information
The study was funded by Danish Cancer Society grant R192-A11536. T Juul was partly supported by Novo Nordisk Foundation grant NNF19OC0022988.

Abstract

Aim: The air

term gastro

their wish fc

Method: A

after surger

were referre

Treatment e

five-dimensi

Results: Ov

vey and 767

referred for

majority we

Patients rep

loose stools

low anterior

patients wit

Our main ei

baseline (ba

bowel funct

Conclusion:

need of trea

ciplinary tea

KEYWORD!

bowel dysfun

The study is registered at [ClinicalTrials.gov](#) (NCT number: NCT04003181).

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](#) license. © 2022 The Authors. *Colorectal Disease* published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.

600 | [wileyonlinelibrary.com/journal/codi](#)

Members of the Danish Cancer Society Centre for Research on Survivors



Received: 22 April 2022 | Revised: 8 September 2022 | Accepted: 1 October 2022
DOI: 10.1111/codi.16409

ORIGINAL ARTICLE

Chronic loose stools following right-sided colon cancer and the association with and small intestinal bacterial overgrowth

Helene Mathilde Larsen^{1,2} | Klaus Krogh^{1,3} | Mette Mejlbj Hansen³ | Anne K Arveschoug⁴ | Peter Asbjørn Mohr Drewes^{1,5} | Katrine Jøssing Emmertsen¹
Janne Ladefoged Fassov^{1,3}

Abstract

Aim: The air

term gastro

their wish fc

Method: A

after surger

were referre

Treatment e

five-dimensi

Results: Ov

vey and 767

referred for

majority we

Patients rep

loose stools

low anterior

patients wit

Our main ei

baseline (ba

bowel funct

Conclusion:

need of trea

ciplinary tea

KEYWORD!

bowel dysfun

The study is registered at [ClinicalTrials.gov](#) (NCT number: NCT04003181).

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](#) license. © 2022 The Authors. *Colorectal Disease* published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.

600 | [wileyonlinelibrary.com/journal/codi](#)

ACTA ONCOLOGICA
2019, VOL. 58, NO. 5, 776–781
<https://doi.org/10.1080/0284186X.2018.1562211>

ORIGINAL ARTICLE

Clinical evaluation and treatment of chronic bowel symptoms in the colon and pelvic organs

Helene Mathilde Larsen^{a,b}, Mette Borre^{a,c}, Peter Christensen^{a,b}, Asbjørn Mohr Drewes^{a,c} and Janne Fassov^{a,c}

^aDanish Cancer Society Centre for Research on Survivorship and Late Adverse Effect, Aarhus, Denmark; ^bDepartment of Surgery, Aarhus University Hospital, Aarhus, Denmark; ^cMech-Sense, Department of Gastroenterology, Aalborg University Hospital, Aalborg, Denmark

ABSTRACT

Background: Chronic gastrointestinal symptoms are common among patients treated with surgery or radio-/chemotherapy for cancer in the pelvic organs. However, little is known about the underlying pathophysiology behind symptoms or the effect of treatment. The aim of the present study was to evaluate the clinical evaluation and treatment of patients with chronic bowel symptoms in the colon and pelvic organs.

Material and methods: All patients referred to our department of gastroenterology with chronic bowel symptoms after treatment for cancer in the colon and pelvic organs were prospectively evaluated.

Results: In total, 60 patients had been referred. The patients were treated for cancer in the colon and pelvic organs (n = 31), rectum (n = 14), anal canal (n = 4), cervix (n = 2), sigmoid colon (n = 1), rectum (n = 1), rectum (n = 1), anal canal (n = 4), cervix (n = 2), ovary (n = 2), and prostate (n = 1). The median time from cancer treatment to symptom onset was 10 years (range 1–36 years). Symptoms mainly included frequent bowel movements (median 4–5 times per day), urgency for defecation (57%), and fecal incontinence (50%). A specific cause was found in 48 (80%) of the patients and 21 (35%) had more than one cause.

Conclusion: Most patients referred to our department of gastroenterology with chronic bowel symptoms after treatment for cancer in the colon and pelvic organs were prospectively evaluated. The results show that chronic bowel symptoms are common after treatment for cancer in the colon and pelvic organs. The most common symptoms were frequent bowel movements, urgency for defecation, and fecal incontinence. A specific cause was found in 48 (80%) of the patients and 21 (35%) had more than one cause. Treatment included dietary intervention (n = 20). Major improvement in bowel symptoms was seen in 14 (70%) patients. While another 27 (45%) reported some improvement, 13 (65%) patients remained symptomatic. Patients with chronic bowel symptoms following cancer treatment will benefit from expert clinical evaluation and targeted treatment.

Introduction

Survival after treatment for cancer in the pelvic region has improved significantly during the last decades. Consequently, late complications to treatment have attracted more attention. Gastrointestinal symptoms are common, not only after treatment for colon or rectal cancer, but also after other cancers in the pelvic region. Thus, 15–66% of patients with colorectal, urological, or gynecological cancers treated with surgery or radio-/chemotherapy suffer from chronic gastrointestinal symptoms [1]. Loose stools, soiling, and frequent bowel movements are common symptoms after surgical resection of the rectum and, in particular after right-sided colectomy if more than 10 cm of the terminal ileum has been resected [2]. Long-term functional problems following treatment for rectal cancer have been described in detail as the Low Anterior Resection Syndrome (incontinence for flatus and liquid stools, frequent bowel movements, clustering, and urgency for defecation) [3,4]. In addition, radiotherapy for



UGESKRIFT FOR LÆGER

Statusartikel

Ugeskr Læger 2022;184:V04220267

Gastrointestinale senfølger til behandling af kræft i bækkenorganer

Janne Fassov^{1,2}, Katrine Emmertsen^{2,3}, Therese Juul^{2,4}, Peter Christensen^{2,4}, Asbjørn Mohr Drewes^{2,5}, Søren Laurberg^{2,4} og Klaus Krogh^{1,2}

¹) Lever-, Mave- og Tarmsygdomme, Aarhus Universitetshospital, 2) Danish Cancer Society Centre for Research on Survivorship and Late Adverse Effects after Cancer in the Pelvic Organs, 3) Mave- og Tarmkirurgisk Afdeling, Regionshospitalet Randers, 4) Mave- og Tarmkirurgisk Afdeling, Aarhus Universitetshospital, 5) Mave- og Tarmsygdomme, Aalborg Universitetshospital

Ugeskr Læger 2022;184:V04220267

HOVEDBUDSKABER

- Antallet af langtidsoverlevere efter kræft i det lille bækken er stigende.
- Gastrointestinale senfølger til kræftbehandling er kendte, invalidiserende og livsbegrænsende.
- Udredning og behandling i dedikerede, tævelfaglige senfølgeklinikker kan hjælpe mere end halvdelen af patienterne.

Denne statusartikel har til formål at give overblik over gastrointestinale (GI) senfølger efter behandling af kræft i bækkenorganerne herunder at beskrive udredning og behandlingsmuligheder. GI-senfølger i form af hyppige, løse, fragmenterede afførringer, svær imperforationstræng, faekal inkontinens, tomningsbesvær og mavesmerter har negativ indvirkning på daglig aktivitet og medvirker til betydeligt reduceret livskvalitet [1]. Tidlig diagnostik og bedre behandlingsmuligheder har medført, at antallet af langtidsoverlevere efter kræftbehandling er stigende. I 2030 estimeres der at være 4 mio. langtidsoverlevere i Storbritannien og 22 mio. i USA. Cirka 20–25% har kroniske fysiske problemer [2].

BAGGRUND

Kolorektal- og analkræft

Efter højresidig hemikolektomi ± adjuvante (adj.) kemoterapi for kolonkræft oplever ca. 20% løs afføring, øget afførfrekvens og/eller natlig afføring [3]. En dansk tværsnitstundersøgelse viser, at 19% har daglig imperforationstræng og 29% har faekal inkontinens [4]. Afførforsyretelsen kan være ledsgaget af kvalme, luftgener samt mavesmerter og ubehag [5].

Efter sigmoidumresektion ± adj. kemoterapi ses hos 21% faekal inkontinens, hos 47% faekal imperforationstræng, øget afførfrekvens og/eller natlig afføring [3]. En dansk tværsnitstundersøgelse viser, at 19% har daglig imperforationstræng og 29% har faekal inkontinens [4]. Afførforsyretelsen kan være ledsgaget af luftgener samt mavesmerter og ubehag [5].

I det første år efter total mesorektal excision eller parietal mesorektal excision ± adj. kemoterapi for endetarmskraft har 80% symptomer på low anterior resection syndrome (LARS) karakteriseret ved hyppige, fragmenterede afførringer vekslende i konsistens, tomningsbesvær samt faekal imperforation og inkontinens [7].

40% har vedvarende symptomer efter et år [8].

Ugeskr Læger 2022;184:V04220267

Side 1 af 8

ORIGINAL ARTICLE

ORIGINAL ARTICLE
Bowel dysfunction following pelvic organ cancer: a prospective study on the treatment effect in nurse-led late sequelae clinics

Mira Mekhail^{a,b,c}, Helene M. Larsen^{a,c,f}, Michael B. Lauritzen^{c,d}, Ole Thorlaciuss-Ussing^{c,d,e}, Søren Laurberg^{a,c}, Klaus Krogh^{c,f}, Asbjørn M. Drewes^{c,g}, Peter Christensen^{a,c} and Therese Juul^{a,b,c,f}

^aDepartment of Surgery, Aarhus University Hospital, Aarhus, Denmark; ^bDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark; ^cDanish Cancer Society Centre for Research on Survivorship and Late Adverse Effects after Cancer in the Pelvic Organs, Aarhus University Hospitals, Aarhus and Aalborg, Denmark; ^dDepartment of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark; ^eDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; ^fDepartment of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark

ABSTRACT

Background: Bowel dysfunction following cancer treatment can significantly impact the quality of life (QoL). The present study aimed to evaluate the feasibility of a nurse-led late sequelae clinics.

Material and methods: Treatment effects were monitored prospectively by bowel measures collected at baseline and discharge. Change in bowel function was evaluated by 15 bowel symptoms collected at the St. Mark's Incontinence Score, the Patients' Assessment of Constipation-Symptoms (PAC-S) and the EuroQol 5-dimension 5-level

Results: From June 2018 to December 2021, 380 cancer survivors (46% rectal, 15% gynaecological, 13% anal, 12% colon, 12% prostate, and 2% other cancers) completed a baseline questionnaire and treatment for bowel dysfunction. At referral, 96% of patients were multisympathetic. The most common treatment was defaecation (93%), emptying difficulties (60%), fragmented defaecation (9%), and straining defaecation (7%).

started treatment for bowel incontinence. The most frequent symptoms were faecal urgency (95%), fragmented stools (92%), flatus/faecal incontinence (flatus 89%, liquid 59%, solid 33%), and obstructed defaecation. In total, 169 patients were discharged from the clinics in the follow-up period. At discharge, 69% received conservative treatment only and 24% also received transanal irrigation. 4% were surgically treated; 3% discontinued treatment. Improvements were seen in all 15 bowel symptoms ($p < 0.001$), the mean St. Mark's Incontinence Score (12.0 to 9.9, $p < 0.001$), the mean PAC-SYM score (1.04 to 0.84, $p < 0.001$) and the mean EQ-5D-ML utility score (0.78 to 0.84, $p < 0.001$). Self-rated bowel function improved in 85% of cases and the impact of bowel function on QoL improved in 46%.

Concepts

Gene

© 2011 Pearson Education, Inc.

Back to [Table of Contents](#)

Pelvis includes

EQ

one
mo

6 30 6 3

(Q) 8 - (Q)

0.75 **0.6**



... for pelvic organ cancer constitutes a major challenge.

jens@rm.dk Department of Surgery, Aarhus University Hospital, Department of Clinical Oncology, Effects after Cancer in the Pelvic Organs, Aarhus University, Denmark

CONTACT Mira Mekhail mirmek@mcgill.ca
Cancer Society Centre for Research on Survivorship and Late Adverse Effects after Cancer

and Aalborg, Denmark
© 2023 Acta Oncologica Foundation

Generisk QOL EQ-5D-5L 0.78 – 0.84 (p<0.001)





'Jeg kan gå tur med hunden uden'

'Jeg inviterede til stor fødselsdagsfest uden at bekymre mig'

'Jeg har ikke længere en taske med skiftetøj og bleer med mig'

'Nu kan jeg igen deltage i mandeklubben..'

KLINIK FOR SENFØLGER TIL KRÆFT I BÆKKENORGANERNE


Oprettet på Aarhus Universitetshospital og
Aalborg Universitetshospital med driftsstøtte
fra Region Midtjylland og Region Nordjylland

NATIONAL UDBREDELSE I GANG

Region Hovedstaden, Herlev

Region Sjælland, Køge

Region Syd, Svendborg/Odense/Vejle



Nationale kliniske retningslinjer: kolorektal cancer og anal cancer

Søg på hjemmesiden... 

DANSKE MULTIDISCIPLINÆRE CANCER GRUPPER  DMCG.dk

Om DMCG.dk Kliniske retningslinjer DMCG udvalg Årberetninger og udgivelser Danske Kræftforskningsdage Kontakt

Du er her: Kliniske retningslinjer > Kliniske retningslinjer opdelt på DMCG > Kolorektalcancer > Management of treatment-related sequelae following colorectal cancer

Udskriv 

Kliniske retningslinjer Management of treatment-related sequelae following colorectal cancer

Kliniske retningslinjer opdelt på DMCG

Kolorektalcancer

Management of treatment-related sequelae following colorectal cancer

Anbefalinger

- + Fokus på senfølger i opfølgningsprogrammerne
- + Psykosociale senfølger
- + Senfølger i mave-tarm-kanalen efter koloncancer
- + Senfølger i mave-tarm-kanalen efter rektumcancer
- + Stomier
- + Senfølger i urinvejene
- + Seksuelle senfølger

ACTA ONCOLOGICA
2021, VOL. 60, NO. 12, 1688–1701
<https://doi.org/10.1080/0384186X.2021.1983208>

Taylor & Francis
Taylor & Francis Group

Check for updates

REVIEW

Management of late adverse effects after chemoradiation for anal carcinoma

Susanne Haas^a, Anette H. Mikkelsen^b, Camilla Kronborg^c, Birthe T. Oggesen^d, Pia Moeller Faaborg Eva Serup-Hansen^e, Karen-Lise G. Spindler^f and Peter Christensen^a

^aDanish Cancer Society, National Research Centre for Survivorship and Late Adverse Effects following Pelvic Organ Cancer Surgery, Aarhus University Hospital, Aalborg, Denmark; ^bSexological Center, Aalborg University Hospital, Aalborg, Denmark; ^cDepartment of Surgery, Herlev Hospital, Herlev, Denmark for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; ^dDepartment of Oncology, Herlev Hospital, Herlev Hospital of Surgery, Vejle Hospital, Danish Colorectal Cancer Centre South, Vejle, Denmark; ^eDepartment of Oncology, Herlev Hospital, Herlev Hospital, Denmark; ^fDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark

Received: 29 April 2022 | Revised: 15 July 2022 | Accepted: 21 July 2022
DOI: 10.1111/ctod.16299

GUIDELINES

Management of treatment-related sequelae following colorectal cancer

Susanne Haas^{1,2} | Anette Høj Mikkelsen³ | Camilla Jense尼us Skovhus Kronborg⁴ | Birthe T. Oggesen⁵ | Pia F. Møller⁶ | Janne Fassov^{1,7} | Nina Abild Frederiksen⁸ | Marianne Krogsgaard⁸ | Charlotte Graugaard-Jensen⁹ | Lise Ventzel¹⁰ | Peter Christensen^{1,11} | Katrine Jøssing Emmertsen^{1,2}

ABSTRACT
Background and purpose: Significant improvements in the treatment of anal cancer have produced a growing population of anal cancer survivors. These patients often experience late adverse effects related to their treatment. Research has revealed substantial unmet needs because of long-term symptoms and functional impairments after treatment which may negatively affect health-related quality of life. The purpose of the present guidelines is to review the scientific evidence for the management of late adverse effects after (chemo)radiotherapy (CRT) for anal cancer and to extrapolate knowledge from other pelvic malignancies treated with pelvic CRT so that they may guide the clinical management of late adverse effects.

Materials and methods: Relevant studies were systematically searched in four databases from their inception to June 2020 (no language limitation) and guidelines were searched in 16 databases, focusing on bowel dysfunction, psychosocial aspects, pain and sexual and urinary dysfunction. The guidelines were developed by a panel of experts using the Oxford Centre for Evidence-based Medicine levels of evidence and grades of recommendation.

Scientific evidence: Late adverse effects after CRT for anal cancer are associated with a low overall quality of life among survivors. The most pronounced late adverse effects are bowel dysfunction (present in up to 78%), urinary dysfunction (present in up to 45%) and sexual dysfunction (present in up to 90% of men and up to 100% of women). Only indirect data on adequate treatment options of these late adverse effects for anal cancer are available.

Conclusion: Quality of life and late adverse effects should be monitored systematically following treatment for anal cancer to identify patients who require further specialist evaluation or support. Increased awareness of the extent of the problem may serve to stimulate and facilitate multidisciplinary collaboration, which is often required.

Abstract
Aim: Colorectal cancer survivors are one of the most rapidly growing groups of patients living with and beyond cancer. In a national multidisciplinary setting, we have examined the extent of late treatment-related sequelae in colorectal cancer survivors and present the scientific evidence for management of these conditions in this patient category with the aim of facilitating identification and treatment.
Method: A systematic search for existing guidelines and relevant studies was performed across 16 and 4 databases, respectively, from inception to 2021. This yielded 13 guidelines and 886 abstracts, of which 188 were included in the finalized guideline (231 included for full text review). Secondly, bibliographies were cross-referenced and 53 additional articles were included.
Results: Symptoms have been divided into overall categories including psychosocial, bowel-related, urinary, sexual (male and female), pain/neuropathy and fatigue symptoms or complaints that are examined individually. Merging and grading of data resulted in 22 recommendations and 42 management strategies across categories. Recommendations are of a more general character, whereas management strategies provide more practical advice suited for initiation on site before referral to specialized units.
Conclusion: Treatment-related sequelae in colorectal cancer survivors are common and attention needs to be focused on identifying patients with unmet treatment needs and the development of evidence-based treatment algorithms.

Background and purpose
Squamous cell carcinoma of the anal canal (anal cancer) is relatively rare, but the incidence has been increasing over the past two decades, whereas age at time of diagnosis has followed a decreasing trend [1,2]. The increasing incidence of anal cancer in men and women may be accounted for by an increase in the prevalence of exposures, such as cigarette smoking, anal intercourse, human papilloma virus (HPV) infection, and growth in the number of lifetime sexual partners [1]. In Denmark, the incidence rate of HPV-associated anal cancers has increased significantly, whereas that of non-HPV-associated histological types has levelled out or even declined in the 30-year period during which observation has been in place indicating that vaccines against HPV may play an important role in the prevention of anal cancer and its precursor lesions [3].

The standard of care for anal cancer is (chemo)radiotherapy (CRT). The purpose of CRT is to control the tumour, preserve sphincter function and best possible quality of life (QoL). However, CRT has never been compared directly, but in addition to preserving sphincter function, it has shown to yield better local control and survival than surgery [4]. In case of cancer recurrence, surgery should be offered. CRT for anal cancer involves chemotherapy delivered to the anal tumour and regional lymph nodes, and a lower dose delivered to the rectum. Organs that are often affected by CRT are the small and large bowel, the bladder, genitalia, male genitalia, the skin, and viscera.

Significant improvements in anal cancer treatment have been made, particularly in the last decade. However, surviving anal cancer often co-exists with long-term sequelae.

KEYWORDS
colorectal cancer, colon cancer, long-term sequelae, rectal cancer, sequelae, treatment-related sequelae

CONTACT Peter Christensen  petchris@rm.dk  Danish Cancer Society, National Research Center for Survivorship and Late Adverse Effects following Pelvic Organ Cancer, Department of Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus, C119-136, Denmark

© 2021 Acta Oncologica Foundation

Funding Information
Kraftens Bekampelse; the Danish Cancer Society

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.

Colorectal Disease. 2023;25:458–488.

458 | vileyonlinelibrary.com/journal/cod

Pakkeforløb for kræft i tyk- og endetarm

For fagfolk

4.2. Specifikke senfølger til kræft i tyk- og endetarm

Op imod 40% af patienter behandlet for kræft i tyk- og endetarm får væsentlige senfølger til deres kræftbehandling. DCCG har udarbejdet kliniske retningslinjer⁽⁵⁾ for håndtering af senfølger til kræft i tyk og endetarm, med anbefalinger til opsporing, udredning og behandling af senfølgerne. For en mere uddybende beskrivelse se disse.

handling af senfølgerne. For en mere uddybende beskrivelse se disse.

Senfølger til kræft i tyk- og endetarm er sjældent isoleret til enkelte organer, men er ofte et resultat af flere abnorme funktioner, som kan give symptomer i form af tarmproblemer, smærter, vandladningsproblemer, seksuelle problemer og psykosociale problemer. Senfølger kan i vidtgående grad påvirke patientens sociale aktiviteter og livskvalitet. Iværksættelse af de rette interventioner kan dog medføre markante forbedringer.

Ved konstatering af senfølger, er det den afdeling, som på det givne tidspunkt har patienten i behandling eller i et opfølgningsforløb, som er ansvarlig for, at senfølgerne vurderes af de rette fagpersoner fra relevante specialer. I en del tilfælde konstateres senfølgerne i almen praksis, som derved er ansvarlige for at håndtere senfølgerne eller henvise til vurdering. Det kan være relevant med henvisning til en afklarende samtale i kommunen, og

Forpligtende standarder! Kvalificeret behandling!



Alle kræftformer.
Kliniske retningslinjer.

Specialiseret
behandlingstilbud.
Organspecifikke + generelle.

**Senfølger efter
kræft**

Senfølgeklinikker
i alle regioner

Kræftplan V

ON THE ROAD TO SUCCESS,
THERE ARE NO SHORTCUTS.

JOIN OUR TEAM
600-669-0322
shaffertrucking.com

OUR MOST
VALUABLE
RESOURCE SITS
63 FEET AHEAD.



C 24D

TAK FOR OPMÆRKSOMHEDEN



@AUHsurgery
@PeterCh12345
@Senfoelger

#SamarbejdeOmKræft

#DKD2023



AUH Surgery
Surgical Research

